1. Home
  2. SVM vs TRAX Comparison

SVM vs TRAX Comparison

Compare SVM & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silvercorp Metals Inc.

SVM

Silvercorp Metals Inc.

N/A

Current Price

$7.26

Market Cap

2.1B

ML Signal

N/A

TRAX

First Tracks Biotherapeutics Inc. Ordinary Shares

N/A

Current Price

$44.45

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SVM
TRAX
Founded
2003
2025
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2005
2026

Fundamental Metrics

Financial Performance
Metric
SVM
TRAX
Price
$7.26
$44.45
Analyst Decision
Buy
Strong Buy
Analyst Count
6
12
Target Price
$14.25
★ $75.17
AVG Volume (30 Days)
★ 2.6M
545.7K
Earning Date
11-05-2026
11-03-2026
Dividend Yield
★ 0.33%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.19
N/A
Revenue Next Year
$69.05
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.11
$15.69
52 Week High
$15.77
$54.78

Technical Indicators

Market Signals
Indicator
SVM
TRAX
Relative Strength Index (RSI) 32.11 50.77
Support Level N/A $40.72
Resistance Level $10.02 $48.94
Average True Range (ATR) 0.48 3.21
MACD -0.06 -0.76
Stochastic Oscillator 2.28 14.42

Price Performance

Historical Comparison
SVM
TRAX

About SVM Silvercorp Metals Inc.

Silvercorp Metals Inc is engaged in the acquisition, exploration, development, and mining of mineral properties. The Company's producing mines are located in China, and current exploration and development projects are located in China, Ecuador and Kyrgyz Republic. The company operates in single segment. The Company mainly produces and sells silver, lead, zinc, gold and other metals. The company's producing projects are Ying Mining District, GC Mine; construction projects are El Domo; permitting project is BYP Mine; development project includes Condor, Tulkubash/Kyzyltash.

About TRAX First Tracks Biotherapeutics Inc. Ordinary Shares

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

Share on Social Networks: